Pharmacokinetics and Safety in Healthy Volunteers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

327 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2014-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate the pharmacokinetics, safety and tolerability of BI695501 and to establish pharmacokinetic similarity of BI 695501 to adalimumab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

NCT01505491

Healthy

COMPLETED PHASE1

Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

NCT02640612

Arthritis, Rheumatoid

COMPLETED PHASE3

Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

NCT04439929

Healthy Participants

COMPLETED PHASE1

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

NCT02137226

Arthritis, Rheumatoid

COMPLETED PHASE3

A Clinical Study With Adalimumab Biosimilar

NCT06291948

Pharmacokinetics Safety Issues

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 695501

Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501

Group Type EXPERIMENTAL

BI 695501

Intervention Type DRUG

BI 695501 single s.c. injection

adalimumab-EU source

Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source

Group Type ACTIVE_COMPARATOR

adalimumab-EU source

Intervention Type DRUG

adalimumab-EU source single s.c. injection

adalimumab-US source

Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source

Group Type ACTIVE_COMPARATOR

adalimumab-US source

Intervention Type DRUG

adalimumab-US source single s.c. injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 695501

BI 695501 single s.c. injection

Intervention Type DRUG

adalimumab-EU source

adalimumab-EU source single s.c. injection

Intervention Type DRUG

adalimumab-US source

adalimumab-US source single s.c. injection.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Healthy males according to the following criteria:

1. Based upon a complete medical history, including the physical examination, vital signs (blood pressure \[BP\] and pulse rate \[PR\]), 12-lead electrocardiogram (ECG), and clinical laboratory tests;
2. Age-greater than or equal to 18 years and less than or equal to 55 years;
3. Body mass index (BMI) =18.5 to =29.9 kg/m2; and
4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation.

Exclusion Criteria

1. Any clinically relevant abnormal finding of the medical examination (including blood pressure (BP), pulse rate (PR), and electrocardiogram (ECG) deviating from normal and of clinical relevance;
2. Any evidence of a clinically relevant previous or concomitant disease as judged by the investigator including gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, hormonal disorders, or diseases of the central nervous system (such as epilepsy), psychiatric disorders, or neurological disorders;
3. History of relevant orthostatic hypotension, fainting spells, or blackouts;
4. Chronic or relevant acute infections. A negative result for human immunodeficiency virus (HIV), Hepatitis B (Hep B), and hepatitis C (Hep C) is required for participation;
5. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients);
6. Intake of prescribed or over-the-counter drugs with a long half-life (greater than 24 hours) within at least one month or at least 5 half-lives of the respective drug (whichever is longer) prior to administration or during the trial;
7. Previous exposure of a biologic drug;
8. Use of drugs which might reasonably influence the results of the trial prior to dosing and at any time during the trial;
9. Intake of an investigational drug in another trial within two months prior to intake of study medication in this trial or intake of an investigational drug during the course of this trial;
10. Smoker (greater than 10 cigarettes or greater than 3 cigars or greater than 3 pipes/day);
11. Inability to refrain from smoking during days of confinement at the trial site;
12. History of alcohol abuse (estimated average more than 4 units/day);
13. Unwillingness/inability to refrain from intake of alcoholic beverages from 48 hours prior to the study medication administration and until Day 7 post study medication administration;
14. Unwillingness/inability to limit alcohol intake to a maximum of three units per day until e.o.s.;
15. Current drug abuse;
16. Blood donation (more than 100 mL within four weeks prior to administration of the study medication or during the trial);
17. Vigorous exercise 72 hours prior to dosing. Unwilling to avoid vigorous exercise for 7 days post dosing. Contact sport should be avoided during the entire study;
18. Any out-of-range laboratory values considered clinically significant by the investigator; subjects with creatine kinase (CK) values three times the upper limit of normal (ULN) at Day -1 are excluded from participation;
19. Subjects considered unsuitable for inclusion by the investigator (e.g., inability to understand and comply with the study requirements or presence of any condition which, in the opinion of the investigator, would not allow safe participation in the study); or
20. Inability to comply with dietary regimen of trial site.
21. Subjects with known Human immunodeficiency virus (HIV), Acquired Immunodeficiency Syndrome, other clinically significant immunological disorders, or auto-immune disorders, (e.g., Rheumatoid arthritis (RA), lupus erythematosus, scleroderma, etc.);
22. Subject has received a live or attenuated vaccine within 12 weeks prior to enrolling in the trial; or
23. Positive finding in Interferon-gamma-release assay testing (IGRA-T). In cases where at the screening visit the IGRA result is indeterminate, the subject will have a PPD skin test performed, provided that the screening period timeframe can be maintained. If not, the subject will not be enrolled in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes